Novel SLGP protein and nucleic acid molecules and uses therefor
AssigneeMillennium Pharmaceuticals, Inc.
InventorFong-Ying Tsai
Life of this patent
Estimating the term…
Abstract
The invention provides isolated nucleic acids molecules, designated SLGP nucleic acid molecules, which encode novel GPCR family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLGP nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an SLGP gene has been introduced or disrupted. The invention still further provides isolated SLGP proteins, fusion proteins, antigenic peptides and anti-SLGP antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Claims56
An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:17, or a complement thereof.
An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:3, SEQ ID NO:19, or a complement thereof.
An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:17, or a complement thereof.
An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:3, SEQ ID NO:19, or a complement thereof.
An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:18, or a complement thereof.
An isolated nucleic acid molecule which encodes a polypeptide consisting of the amino acid sequence set forth in SEQID NO:2, SEQID NO:18, or a complement thereof.
An isolated nucleic acid molecule comprising a nucleotide sequence encoding a mammalian G protein-coupled receptor, wherein the nucleotide sequence hybridizes to a nucleic acid molecule consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:17, or SEQ ID NO:19 at 6×SSC at 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 50-65° C.
An isolated nucleic acid molecule consisting of a nucleotide sequence encoding a mammalian G protein-coupled receptor, wherein the nucleotide sequence hybridizes to a nucleic acid molecule consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:17, or SEQ ID NO:19 at 6×SSC at 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 50-65° C.
An isolated nucleic acid molecule comprising a nucleotide sequence encoding a mammalian G protein-coupled receptor polypeptide, wherein the nucleotide sequence is at least 90% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:17, SEQ ID NO:19, or a complement thereof, and wherein said percent identity is calculated using the NBLAST program for comparing nucleotide sequences, using a score of 100 and a wordlength of 12.
An isolated nucleic acid molecule consisting of a nucleotide sequence encoding a mammalian G protein-coupled receptor polypeptide, wherein the nucleotide sequence is at least 90% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:17, SEQ ID NO:19, or a complement thereof and wherein said percent identity is calculated using the NBLAST program for comparing nucleotide sequences, using a score of 100 and a wordlength of 12.
A method for identifying a compound capable of treating a cellular proliferation, growth, differentiation, or migration disorder comprising assaying the ability of the compound to modulate SLGP nucleic acid expression or SLGP polypeptide activity, thereby identifying a compound capable of treating a cellular proliferation, growth, differentiation, or migration disorder.
A method for identifying a compound capable of modulating an endothelial cell process comprising:
- a) contacting an endothelial cell with a test compound;
- and
- b) assaying the ability of the test compound to modulate the expression of an SLGP nucleic acid or the activity of an SLGP polypeptide,
- thereby identifying a compound capable of modulating an endothelial cell process.
A method for modulating an endothelial cell process comprising contacting an endothelial cell with an SLGP modulator, thereby modulating said endothelial cell process.
A method for treating a subject having a cellular proliferation, growth, differentiation, or migration disorder characterized by aberrant SLGP polypeptide activity or aberrant SLGP nucleic acid expression comprising administering to the subject an SLGP modulator, thereby treating said subject having a cellular proliferation, growth, differentiation, or migration disorder.
A method for modulating angiogenesis in a subject comprising administering to the subject an SLGP modulator, thereby modulating angiogenesis in said subject.
A method for modulating angiogenesis in a tumor comprising contacting the tumor with an SLGP modulator, thereby modulating angiogenesis in said tumor.
Dependencies are inferred from the claim text.